DOSEGUY

Livagen

guinea pig

Also seen as: KEDA peptide, Lys-Glu-Asp-Ala, KEDA

The Dose Guy’s verdict
Sep 1, 2026
3 sources

Livagen is a liver-tissue bioregulator from the Khavinson peptide program, and the evidence for it is about as thin as this shelf gets. The published record is mostly cell-culture work, human lymphocytes in dishes and rat hepatocytes in flasks, plus one study giving oral livagen to live rats. No human has received livagen in a published study. No dose, no safety profile, no pharmacokinetics. If liver support is the goal, glutathione has human absorption data and NAC is the cheaper workhorse precursor, though neither has been trialed specifically for liver protection in drinkers.

Would I take it?Not with this evidence.

What it is

Livagen is a synthetic tetrapeptide from the Khavinson bioregulator family, a set of short peptides isolated from animal organs and studied in Russian labs since the 1980s for tissue-specific repair and gene-regulation effects. The proposed mechanism is chromatin remodeling: in cultured white blood cells from elderly donors, livagen opened up tightly packed chromatin and activated ribosomal genes, suggesting it could reawaken gene expression that shuts down with age. Whether that happens inside a living person, at any dose, by any route, is untested.

What the research shows

No human trials. Zero. Everything below is animal or in-vitro work. Read it as “interesting,” not “evidence it works in you.”

Mostly cell-culture work, plus one animal study. The mechanism is interesting at the bench and entirely unvalidated in people:

In leukocytes from subjects aged 75 to 88 years, livagen activated ribosomal genes, decondensed chromatin fibrils, and opened pericentromeric structural chromatin in chromosomes 1 and 9.Bull Exp Biol Med 2004 · human leukocytes
In cultured lymphocytes from the same age group, nearly twenty years later, the same lab family found livagen decondensed total heterochromatin but not pericentromeric structural heterochromatin, the opposite result on the same endpoint.Georgian Med News 2023 · human lymphocytes
After two weeks of oral livagen in live rats, digestive enzyme activity decreased in young animals and increased in old ones, usually approaching young control levels.Gerontology 2005 · rat oral
No randomized trial, clinical intervention, human pharmacokinetic study, or clinical safety dataset for livagen exists in the published literature.as of Aug 2026

Realistic protocols

There is no defensible human protocol for livagen. The bioregulator community runs it in short courses, typically 10 to 20 days of subcutaneous injections or sublingual drops, cycled a few times a year. That regimen comes from the general Khavinson bioregulator playbook, not from anything specific to livagen. The tetrapeptide is small enough that oral or sublingual absorption is possible in theory, but nobody has measured it. If liver support is the actual goal, glutathione has human trial data and NAC is the cheaper workhorse precursor. If you run livagen anyway, go low, go short, and do not confuse a chromatin assay in a dish with a reason to expect liver healing. I would call epitalon, the most-studied peptide in this family, thin by any Western standard. Livagen is thinner.

Side effects

No human side-effect data exists:

unknownZero clinical safety data. Nobody has measured what this peptide does in a person, helpful or harmful.
unknownNo consistent community-reported side effects, and no clinical data to check them against.
unknownDrug interactions, contraindications, and long-term effects are completely unmapped.

Where to buy

No live listings from tracked vendors right now.